Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind placebo-controlled induction study of RO7790121 in moderate to severe active Crohn's disease
MOH_2025-03-03_013950Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of afimkibart in Crohn's disease (3 arms), sponsored by Roche. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
afimkibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2025-03-03_013950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-03_013950.